How does biotech insurance differ across pre-IND, clinical-stage, and commercial-stage?

Biotech insurance architecture evolves substantially across the development lifecycle. The right program at each stage looks materially different from the right program at the next stage; programs that are not re-papered at each transition produce coverage gaps that surface only at adverse events.

Pre-IND stage: focus is D&O at $2M-$5M with explicit Side A coverage, IP and tech E&O if licensing platform technology, employment practices for hiring growth, and cyber sized to DMF and pre-clinical data exposure. Clinical trial liability is typically not needed yet.

Phase 1-2 clinical-stage: D&O expands to $5M-$10M as funding rounds close and securities-class-action exposure begins to develop. Clinical trial liability is added at $5M-$10M per trial. Cyber expands to address active CTA data flows. Fiduciary liability if a 401(k) is in place.

IPO-readiness: primary D&O expands to $10M-$25M. Transactional D&O placement at the offering is $25M-$50M. Cyber typically expands at the same time, often with required SOC 2 attestation. Standard E&O, EPL, fiduciary, and clinical trial liability programs are reviewed for IPO-readiness sufficiency.

Commercial-stage: products liability towers are added or expanded, scaled to commercial product distribution. D&O continues to expand. Cyber addresses consumer-facing data flows. Patent infringement defense is typically layered for IP-active operations.